8-K/AAcquisitions & DispositionsExhibits & Filings

Medtronic plc 8-K/A Report, Acquisition Completed (Mar 25, 2015)

Filed March 25, 2015For Securities:MDT

Summary

This 8-K/A filing from Medtronic plc serves as an amendment to its previous report, primarily to include comprehensive financial statements related to its acquisition of Covidien plc. The transaction, which closed on January 26, 2015, involved Medtronic plc acquiring Covidien and then merging Medtronic, Inc. (the U.S. operating subsidiary) into a new Irish entity, ultimately making both Medtronic and Covidien subsidiaries of the newly formed Medtronic plc. For investors, the key takeaway is the formal integration of Covidien's financial performance into Medtronic's reporting. This amendment provides the historical financial data of Covidien and pro forma financial information reflecting the combined entity. This is crucial for understanding the scale, financial health, and potential synergies of the newly enlarged Medtronic plc following this significant transformative acquisition.

Key Highlights

  • 1Medtronic plc (MDT) has officially completed the acquisition of Covidien plc, as detailed in this 8-K/A filing.
  • 2The filing amends a previous report to include detailed historical financial statements of Covidien and pro forma financial information for the combined entity.
  • 3The acquisition closed on January 26, 2015, through a scheme of arrangement and a merger structure.
  • 4Both Medtronic (U.S. operating entity) and Covidien now operate as subsidiaries of the newly formed Irish public limited company, Medtronic plc.
  • 5Key exhibits include audited and unaudited financial statements for Covidien for various periods up to December 2014.
  • 6Pro forma financial statements as of January 23, 2015, are provided to illustrate the financial position of the combined company.
  • 7This filing is essential for investors to assess the financial impact and implications of the Medtronic-Covidien merger.

Frequently Asked Questions

The primary purpose of this Amendment No. 1 to Form 8-K is to provide investors with the necessary financial statements (historical and pro forma) related to Medtronic's acquisition of Covidien, which was not fully included in the original 8-K filing.

The acquisition of Covidien by Medtronic officially closed on January 26, 2015.

The pro forma financial information provides a combined view of Medtronic and Covidien's financial performance and position as if the acquisition had occurred at an earlier date. This helps investors understand the financial scale and potential combined results of the new entity.

Following the transaction, both the original Medtronic (Medtronic, Inc.) and Covidien became subsidiaries of the newly established Irish public limited company, Medtronic plc, which is the parent entity.